3ŒŽ27“ú(æ—¥)@9:00~11:00@C‰ïê パシフィコ横浜 会è°ã‚»ãƒ³ã‚¿ãƒ¼ã€€3F 302 S02 医薬å“ã«ã‚ˆã‚‹æœ‰å®³äº‹è±¡0(ゼãƒï¼‰ã¸ã®æŒ‘戦 ~日本医薬å“安全性å¦ä¼šè¨ç«‹ã‚’起点ã¨ã—ã¦ï½ž Challenge to Turn Adverse Drug Event into a Zero ~Starting from the Establishment of Japanese Society of Drug Safety~ オーガナイザー:宇野 å‹æ¬¡ã€å‰ç”° é ¼ä¼¸ S02-1 日本医薬å“安全性å¦ä¼šãŒæå”±ã™ã‚‹ã€Œè¢«ç–‘薬剤ã¨æœ‰å®³äº‹è±¡ã®é–¢é€£åº¦è©•ä¾¡åŸºæº–ã€ã¨ã€Œå‰¯ä½œç”¨é‡ç¯¤åº¦ï¼ˆã‚°ãƒ¬ãƒ¼ãƒ‰ï¼‰åˆ¤å®šåŸºæº–〠“Criteria for the relation degree between suspected drugs and AE†and “Criteria for seriousness (grade of severity) of ADR†Advocated by Japanese Society of Drug Safety ƒVƒ“ƒ|ƒWƒXƒg F ○齊藤 幹央 S02-2 アレルギー性副作用ã®ç™ºç—‡æ©Ÿåºã€èª˜ç™ºè¦å› ãŠã‚ˆã³å›žé¿å¯¾ç–ã®æ¤œè¨Žã®æœ‰ç”¨æ€§ Utility studying developmental the mechanisms, induction factors and prevention measures in allergic side effects of drug ƒVƒ“ƒ|ƒWƒXƒg F ○宇野 å‹æ¬¡ S02-3 ä¸æ¯’性副作用ã®ç™ºç—‡æ©Ÿåºã€èª˜ç™ºè¦å› ãŠã‚ˆã³å›žé¿å¯¾ç–ã®æ¤œè¨Žã®æœ‰ç”¨æ€§ï½žç‰¹ã«æ…¢æ€§è…Žè‡“ç—…ã«ç€ç›®ã—ã¦ï½ž Utility studying development of the mechanisms, induction factors and prevention measures in toxic side effects of drug. —Especially forcusing chronic kidney disease— ƒVƒ“ƒ|ƒWƒXƒg F ○平田 純生 S02-4 病院薬剤師ã«ã‚ˆã‚‹åŒ»è–¬å“ã®å®‰å…¨æ€§ã¸ã®å–り組㿠The approach to drug safety by hospital pharmacists ƒVƒ“ƒ|ƒWƒXƒg F â—‹é‡Žæ‘ å‰›ä¹… S02-5 薬局薬剤師ã«ã‚ˆã‚‹åŒ»è–¬å“ã®å®‰å…¨æ€§ã¸ã®å–り組㿠The approach to drug safety by pharmacy pharmacists ƒVƒ“ƒ|ƒWƒXƒg F ○神浦 茉奈実ã€å±±æœ¬ 京ã€å»£ç”° æ†²å¨ ŒŸõƒy[ƒW‚É–ß‚é